Saturday, September 23, 2023
Saturday, September 23, 2023

Karger Publishers New Journal – Immune System

Karger Publishers’ new journal Immune System features Open Access-based original research and reviews reporting on translational and clinical studies encompassing all fields of immunology with the intention of bridging clinical research with preclinical and translational investigations. With the launch of this new journal, the company seeks to fulfill a strong need in the scientific community for an open and up-and-coming forum for current basic and applied immunological research. The journal will emphasize evidence-based clinical and laboratory research with statistically valid results that clearly help to advance the future of science.

The world-renowned editors-in-chief, Désirée Larenas-Linnemann, Hospital Medica Sur, Mexico City, Mexico, along with Florent Ginhoux, A*Star, Singapore, are specifically welcoming intra- and interdisciplinary research on Environmental Immunology, Immunomics, Immunotherapy, including but not restricted to immune aspects of allergies, respiratory tract, skin, autoimmune and neurodegenerative disorders. The editors are looking for cutting-edge scientific research, systematic reviews, well-elaborated clinical cases and case-series. The transfer of information from fundamental research to clinical research and clinical practice – that is from lab bench to bed — is particularly welcome.

“Immune System is an innovative Open Access journal, welcoming articles with a broad background from basic science to clinical research, as long as the manuscript focuses on certain aspects of our immune response,” states editor-in-chief Désirée Larenas-Linnemann.”

“I’m delighted to announce the launch of our new Karger journal, Immune System, committed to advancing the frontiers of immunology by showcasing and pioneering discoveries that unite clinical and preclinical research. Let’s collaboratively shape a future for immunological research, unbound by limitations” says Marco Casola, Publications Manager of Immunology and Allergy.

Submissions will be accepted on a rolling basis via the journal’s homepage at

Medical Device News Magazine
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) Significantly Improve Overall Survival and Progression-Free Survival in Patients With Previously Untreated Advanced Bladder Cancer in Pivotal Phase...

The EV-302 study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS), compared to chemotherapy. An Independent Data Monitoring Committee determined that OS crossed the pre-specified efficacy boundary at interim analysis. The safety results of the combination are consistent with those of enfortumab vedotin in combination with pembrolizumab previously reported in cisplatin-ineligible patients with la/mUC.

NeuroBo Pharmaceuticals Doses First Patient in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of NASH

"Dosing the first patient, on time, is a testament to our commitment to the clinical development of DA-1241 in patients with NASH," stated Hyung Heon Kim, President and Chief Executive Officer of NeuroBo. "Based on the pre-clinical and clinical evidence generated to date, DA-1241 has demonstrated reduced hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control, and was shown to be well tolerated in both healthy volunteers and in patients with type 2 diabetes mellitus (T2DM). Given this data, we believe that the mechanism of action of this promising cardiometabolic asset will translate into a safe and effective treatment for NASH, a disease with no current treatment options. The two-part design of this trial provides optionality for a potential interim analysis in the first half of 2024 and we expect to report the full data in the second half of 2024."

Medmain Inc. Has Been Selected for the U.S. Market Gateway Accelerator for BioSciences and MedTech

The "U.S. Market Gateway Accelerator for BioSciences and MedTech", sponsored by WorldUpstart, LLC, is an acceleration program that provides medical tech and life sciences startups with a proven track record outside the U.S. with the opportunity to enter and grow their business in the U.S. market.

MindMed Completes Enrollment of Phase 2b Trial of MM-120 in Generalized Anxiety Disorder (GAD)

Robert Barrow, Chief Executive Officer and Director of MindMed. “Thanks in large part to the enthusiasm we have seen regarding MM-120 among investigators and patients, as well as the strong execution of our team, we were able to enroll almost 200 participants in this trial in just over a year. We anticipate sharing topline results during the fourth quarter of this year.”

Signum Surgical Completes Clinical Trial for BioHealx

Moshe Zilversmit, Co-Founder and CEO of Signum Surgical, commented: “The completion of our clinical trial marks a significant milestone for Signum Surgical and our BioHealxTM device. We look forward to submitting our De Novo classification request to the U.S. FDA and the scientific publication of the data in due course, as we seek to bring this novel treatment to market for the benefit of patients, surgeons, and the healthcare system.”

By using this website you agree to accept Medical Device News Magazine Privacy Policy